Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Martin Charles Mihm Jr., M.D.

Co-Author

This page shows the publications co-authored by Martin Mihm and Arthur Sober.
Connection Strength

1.885
  1. Melanoma before and after Thomas B. Fitzpatrick. J Invest Dermatol. 2004 Feb; 122(2):xxxii-xxxiii.
    View in: PubMed
    Score: 0.291
  2. A nonepidermal, primary malignant melanoma arising in a giant congenital melanocytic nevus 40 years after partial surgical removal. J Am Acad Dermatol. 2004 May; 50(5):789-92.
    View in: PubMed
    Score: 0.074
  3. Early death from clinical stage I melanoma. J Invest Dermatol. 1983 Jun; 80(1 Suppl):50s-2s.
    View in: PubMed
    Score: 0.069
  4. Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients. J Invest Dermatol. 1983 Jun; 80(1 Suppl):53s-5s.
    View in: PubMed
    Score: 0.069
  5. Early death from clinical stage I melanoma. J Invest Dermatol. 1983 Jun; 80 Suppl:50s-52s.
    View in: PubMed
    Score: 0.069
  6. Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients. J Invest Dermatol. 1983 Jun; 80 Suppl:53s-55s.
    View in: PubMed
    Score: 0.069
  7. Diagnosis and management of nevi and cutaneous melanoma in infants and children. Clin Dermatol. 2002 Jan-Feb; 20(1):44-50.
    View in: PubMed
    Score: 0.063
  8. Primary melanoma of the skin: recognition and management. J Am Acad Dermatol. 1980 Mar; 2(3):179-97.
    View in: PubMed
    Score: 0.055
  9. Childhood melanoma: a clinicopathological study of 22 cases. Melanoma Res. 1997 Feb; 7(1):63-8.
    View in: PubMed
    Score: 0.045
  10. Acral lentiginous melanoma (including in situ melanoma) arising in association with naevocellular naevi. Melanoma Res. 1996 Jun; 6(3):241-6.
    View in: PubMed
    Score: 0.043
  11. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol. 1994 Aug; 130(8):999-1001.
    View in: PubMed
    Score: 0.038
  12. Very late metastasis (27 years) of cutaneous malignant melanoma arising in a halo giant congenital nevus. Dermatology. 1994; 189(2):162-6.
    View in: PubMed
    Score: 0.036
  13. Estrogen and progesterone receptor analysis in pregnancy-associated melanoma: absence of immunohistochemically detectable hormone receptors. Hum Pathol. 1994 Jan; 25(1):36-41.
    View in: PubMed
    Score: 0.036
  14. Histologic regression in malignant melanoma: an interobserver concordance study. J Cutan Pathol. 1993 Apr; 20(2):126-9.
    View in: PubMed
    Score: 0.034
  15. Precursor lesions of melanoma: do they exist? Semin Surg Oncol. 1992 Nov-Dec; 8(6):358-65.
    View in: PubMed
    Score: 0.033
  16. Multiple primary cutaneous melanomas. Cancer. 1992 Oct 01; 70(7):1911-6.
    View in: PubMed
    Score: 0.033
  17. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors. Hum Pathol. 2013 Jan; 44(1):87-94.
    View in: PubMed
    Score: 0.033
  18. Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic. J Am Acad Dermatol. 2012 Oct; 67(4):727-35.
    View in: PubMed
    Score: 0.032
  19. Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol. 1991 Aug; 139(2):423-35.
    View in: PubMed
    Score: 0.031
  20. Long-term outcome of Spitz-type melanocytic tumors. Arch Dermatol. 2011 Oct; 147(10):1173-9.
    View in: PubMed
    Score: 0.030
  21. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol. 1991 Apr; 22(4):313-9.
    View in: PubMed
    Score: 0.030
  22. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011 Jun; 64(6):1051-9.
    View in: PubMed
    Score: 0.029
  23. Frequency of dysplastic nevi among nevomelanocytic lesions submitted for histopathologic examination. Time trends over a 37-year period. Arch Dermatol. 1990 Apr; 126(4):463-5.
    View in: PubMed
    Score: 0.028
  24. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20; 27(36):6199-206.
    View in: PubMed
    Score: 0.027
  25. The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death. Cancer. 2009 Nov 01; 115(21):5071-83.
    View in: PubMed
    Score: 0.027
  26. Why cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. Cancer. 2009 Nov 01; 115(21):5084-94.
    View in: PubMed
    Score: 0.027
  27. How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. Cancer. 2009 Nov 01; 115(21):5095-107.
    View in: PubMed
    Score: 0.027
  28. Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA. 1987 Dec 04; 258(21):3146-54.
    View in: PubMed
    Score: 0.024
  29. Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer. 2007 Aug 01; 110(3):614-24.
    View in: PubMed
    Score: 0.023
  30. The spectrum of minimal deviation melanoma: a clinicopathologic study of 21 cases. Hum Pathol. 1986 Aug; 17(8):796-806.
    View in: PubMed
    Score: 0.022
  31. Prognosis for polypoidal melanoma is determined by primary tumor thickness. Cancer. 1986 Mar 15; 57(6):1201-3.
    View in: PubMed
    Score: 0.021
  32. Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol. 2005 Sep 20; 23(27):6739-46.
    View in: PubMed
    Score: 0.020
  33. A case-control study of desmoplastic melanoma. J Clin Oncol. 2005 Jun; 23(16_suppl):7529.
    View in: PubMed
    Score: 0.020
  34. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol. 2005 Feb; 52(2):197-203.
    View in: PubMed
    Score: 0.019
  35. Is completion lymphadenectomy after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? Arch Surg. 2004 Apr; 139(4):400-4; discussion 404-5.
    View in: PubMed
    Score: 0.018
  36. Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J Am Acad Dermatol. 1983 Oct; 9(4):563-74.
    View in: PubMed
    Score: 0.018
  37. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol. 1982 Dec; 129(6):2808-15.
    View in: PubMed
    Score: 0.017
  38. Prevalence of melanoma clinically resembling seborrheic keratosis: analysis of 9204 cases. Arch Dermatol. 2002 Dec; 138(12):1562-6.
    View in: PubMed
    Score: 0.017
  39. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg. 1982 Jan; 195(1):35-43.
    View in: PubMed
    Score: 0.016
  40. Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg. 1981 Jul; 194(1):108-12.
    View in: PubMed
    Score: 0.015
  41. Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg. 1981 Jun; 67(6):782-90.
    View in: PubMed
    Score: 0.015
  42. Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study. J Am Acad Dermatol. 2001 Feb; 44(2):207-18.
    View in: PubMed
    Score: 0.015
  43. Prognosis in malignant melanoma. J Am Acad Dermatol. 1980 Nov; 3(5):525-6.
    View in: PubMed
    Score: 0.015
  44. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J. 2000 May-Jun; 6(3):139-45.
    View in: PubMed
    Score: 0.014
  45. Early recognition of cutaneous melanoma. JAMA. 1979 Dec 21; 242(25):2795-9.
    View in: PubMed
    Score: 0.014
  46. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer. 1999 Aug 15; 86(4):617-27.
    View in: PubMed
    Score: 0.013
  47. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg. 1999 Apr; 134(4):381-7.
    View in: PubMed
    Score: 0.013
  48. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998 Oct 27; 95(22):13141-6.
    View in: PubMed
    Score: 0.013
  49. Surgical management of primary cutaneous melanomas of the hands and feet. Ann Surg. 1997 May; 225(5):544-50; discussion 550-3.
    View in: PubMed
    Score: 0.011
  50. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther. 1997 Jan 01; 8(1):111-23.
    View in: PubMed
    Score: 0.011
  51. Increased thickness of pregnancy-associated melanoma. Br J Dermatol. 1995 Jun; 132(6):876-83.
    View in: PubMed
    Score: 0.010
  52. Image analysis of stage 1 melanoma (1.00-2.50 mm): lymphocytic infiltrates related to metastasis and survival. J Cutan Pathol. 1992 Oct; 19(5):390-7.
    View in: PubMed
    Score: 0.008
  53. Occurrence of melanoma in "dysplastic" nevus spilus: report of case and analysis by flow cytometry. J Cutan Pathol. 1992 Oct; 19(5):423-8.
    View in: PubMed
    Score: 0.008
  54. Desmoplastic melanoma: clinicopathologic aspects of six cases. Dermatology. 1992; 185(1):3-8.
    View in: PubMed
    Score: 0.008
  55. Prognosis of clinical stage I melanoma patients with positive elective regional node dissection. J Clin Oncol. 1986 Aug; 4(8):1238-44.
    View in: PubMed
    Score: 0.005
  56. Diagnosis and management of malignant melanoma. Compr Ther. 1986 May; 12(5):23-31.
    View in: PubMed
    Score: 0.005
  57. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol. 1984 Sep; 2(9):994-1001.
    View in: PubMed
    Score: 0.005
  58. Conservative surgical management of superficially invasive cutaneous melanoma. Cancer. 1984 Mar 15; 53(6):1256-9.
    View in: PubMed
    Score: 0.005
  59. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol. 1983 Nov; 9(5):696-708.
    View in: PubMed
    Score: 0.004
  60. Predictors of late deaths among patients with clinical stage I melanoma who have not had bony or visceral metastases within the first 5 years after diagnosis. J Am Acad Dermatol. 1983 Jun; 8(6):864-8.
    View in: PubMed
    Score: 0.004
  61. Increased intraepidermal melanocyte frequency and size in dysplastic melanocytic nevi and cutaneous melanoma. A comparative quantitative study of dysplastic melanocytic nevi, superficial spreading melanoma, nevocellular nevi, and solar lentigines. J Invest Dermatol. 1983 May; 80(5):452-9.
    View in: PubMed
    Score: 0.004
  62. Skin lesions suspected to be melanoma should be photographed. Gross morphological features of primary melanoma associated with metastases. JAMA. 1982 Sep 03; 248(9):1077-81.
    View in: PubMed
    Score: 0.004
  63. Erythema in the primary lesion of superficial spreading melanoma is not of prognostic importance. Br J Dermatol. 1982 Sep; 107(3):339-42.
    View in: PubMed
    Score: 0.004
  64. Cutaneous malignant melanoma: prognostic guidelines for physicians and patients. CA Cancer J Clin. 1982 Mar-Apr; 32(2):113-22.
    View in: PubMed
    Score: 0.004
  65. Narrower margins for clinical stage I malignant melanoma. N Engl J Med. 1982 Feb 25; 306(8):479-82.
    View in: PubMed
    Score: 0.004
  66. The malignant potential of small congenital nevocellular nevi. An estimate of association based on a histologic study of 234 primary cutaneous melanomas. J Am Acad Dermatol. 1982 Feb; 6(2):230-41.
    View in: PubMed
    Score: 0.004
  67. A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg. 1982 Jan; 195(1):44-9.
    View in: PubMed
    Score: 0.004
  68. Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg. 1982 Jan; 195(1):30-4.
    View in: PubMed
    Score: 0.004
  69. The natural break points for primary-tumor thickness in clinical Stage I melanoma. N Engl J Med. 1981 Nov 05; 305(19):1155.
    View in: PubMed
    Score: 0.004
  70. A prognostic model for clinical stage I melanoma of the trunk. Location near the midline is not an independent risk factor for recurrent disease. Am J Surg. 1981 Aug; 142(2):247-51.
    View in: PubMed
    Score: 0.004
  71. A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery. 1981 May; 89(5):599-603.
    View in: PubMed
    Score: 0.004
  72. A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann Surg. 1981 Apr; 193(4):436-40.
    View in: PubMed
    Score: 0.004
  73. Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes. Cancer. 1981 Mar 01; 47(5):955-62.
    View in: PubMed
    Score: 0.004
  74. Clinical characteristics of early cutaneous melanoma. Cancer. 1980 May 15; 45(10):2684-6.
    View in: PubMed
    Score: 0.004
  75. On the prognostic importance of white depressed areas in the primary lesion of superficial spreading melanoma. Cancer. 1979 Jan; 43(1):157-61.
    View in: PubMed
    Score: 0.003
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.